Navigation Links
Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
Date:5/7/2008

MONTVALE, N.J., May 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today that it will report its first quarter 2008 financial results on Wednesday, May 14, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the first quarter results during a conference call the same day, at 9:00 a.m. EST.

Investors and other interested parties may access the call as follows:

Date: Wednesday, May 14, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4441

Telephone (international): 617.597.5396

Participant Passcode: 80809977

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, May 14, 2008, until Wednesday, May 21, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter pass code number 14991737. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About Memory Pharmaceuticals

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memory in artificial atoms
2. Memory Pharmaceuticals Receives Nasdaq Notification
3. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
4. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
5. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
6. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
8. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. ASU researchers improve memory devices using nanotech
11. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Linda, Ca (PRWEB) , ... February 22, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, is ... will place on February 22 and 23, 2017. This premier, online-only conference focused ...
(Date:2/22/2017)... Dublin - Research ... Crop Protection (Bio-Pesticide) Market-By Type, By Application, By End User, By ... offering. ... Biological Crop Protection Market is forecasted to grow at a CAGR ... biopesticide or biological crop protection market is driven by the surging ...
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon HemopurifierĀ® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma ... Tom Perkins as European director. Operating from Pennsideā€™s Zurich headquarters, Pennside Partners, GmbH, ... Perkins joins Pennside after more than a decade with leading market research firm, ...
Breaking Biology Technology:
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):